Moderna (MRNA) is back in focus after first quarter 2026 results, with revenue of US$389 million, a GAAP net loss of US$1.343b, new EU vaccine approvals, and progress in its oncology pipeline.

Moderna's share price has been volatile around the latest results, with a 1-day share price return of 4.25% but a 7-day return of 2.87%. A 90-day gain of 12.09% and year to date share price return of 53.27% contrast with a 3-year total shareholder return of 64.10% and 5-year total shareholder return of 70.17%. This suggests recent momentum is building off a much weaker longer term record as investors weigh new EU vaccine approvals and oncology progress against ongoing losses and litigation costs.

If Moderna's recent moves have your attention, this could be a useful moment to see what else is happening in healthcare related AI, starting with 33 healthcare AI stocks.

With Moderna stock trading around US$47.30, sitting below the average analyst price target and carrying a high value score, the key question is simple: is this a reset that offers upside, or is the market already pricing in its future growth?

Most Popular Narrative: 73% Undervalued

Compared with the last close at $47.30, the most followed narrative pegs Moderna's fair value at $175.00, a large gap that shapes how some investors see the stock.

Despite the defunding of US governmental research and health services, Moderna remains in a commanding fundamental position. The company that made its name during the COVID-19 pandemic developing and manufacturing vaccines for the disease at breakneck pace also happened to have bagged a historic windfall in exchange for its performance. Less well-known is how Moderna reinvested the windfall in the wake of its success. The company has spent years plowing its profits into new innovations while maintaining a relatively pristine balance sheet for a company as large as it is. In biotech it is not uncommon for companies to keep low levels of debt. Moderna is unique among its peers for its particularly low valuation relative to its assets. Currently, the company is trading below its book value, with the potential for explosive growth depending on how any one of its numerous drug and treatment investments pan out. Even without any additional investment in medical innovation, the company has a lot of products in its pipeline ready to go.

This fair value hinges on how that pandemic windfall is converted into future revenue, profit margins, and long run cash flows across a wide mRNA pipeline. The narrative, according to woodworthfund, leans heavily on pipeline breadth, reinvestment of past profits, and balance sheet capacity to fund years of development. Curious which revenue path, profitability profile, and long term discount rate combine to justify $175.00 per share?

Result: Fair Value of $175.00 (UNDERVALUED)

However, this depends on a large, unproven pipeline and comes against a backdrop of recent annual declines in revenue and net income, as well as a sizeable US$2.822b loss.

Another View: Market Ratios Paint a Tougher Picture

That $175.00 fair value is generous compared to how the market currently prices Moderna. At about $47.30, the stock trades on a P/S ratio of 9.7x, which is higher than the peer average of 8.1x and far above the estimated fair ratio of 1.1x. If sentiment shifts closer to that fair ratio, pricing risk could look very different to the user narrative. Which anchor should you really pay more attention to?

Next Steps

Given how mixed the story is so far, it helps to move quickly and weigh the upside yourself. Start by checking the 1 key reward.

Looking for more investment ideas?

If Moderna has sparked your interest, do not stop there. Broaden your watchlist with a few focused stock ideas that could sharpen your overall portfolio thinking.

• Target potential mispricings by scanning companies that stand out on valuation using the 48 high quality undervalued stocks.
• Prioritise staying power in tougher markets by reviewing companies highlighted in the 70 resilient stocks with low risk scores.
• Hunt for future standouts before they become widely followed by checking the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.